The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3447-3455

  Roy, Jocelyn ^a   Paquette, Jean Sébastien ^a   Fortin, Jean François ^a   Tremblay, Michel J ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; PYRIMIDINE DERIVATIVE; RAPAMYCIN; TACROLIMUS; TRANSACTIVATOR PROTEIN; VIRUS RNA;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; EXPRESSION VECTOR; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; LYMPHOID CELL; MESSENGER RNA SYNTHESIS; MURINE LEUKEMIA VIRUS; NONHUMAN; NORMAL HUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; T LYMPHOCYTE; VESICULAR STOMATITIS VIRUS; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ACTINS; BLOTTING, NORTHERN; GENE PRODUCTS, TAT; GENES, REPORTER; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDICATORS AND REAGENTS; LEUKEMIA, T-CELL, ACUTE; PLASMIDS; RNA, MESSENGER; SIROLIMUS; TACROLIMUS; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0036840476     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3447-3455.2002     Document Type: Article

References (78)

1. Abraham, R. T., and G. J. Wiederrecht. 1996. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14:483-510.
2. Adachi, A., H. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
3. 1 of an osteosarcoma cell line. J. Biol. Chem. 268:22825-22829.
4. Bardini, G., M. C. Re, G. Rosti, and A. R. Belardinelli. 1991. HIV infection and bone-marrow transplantation. Lancet 337:1163-1164.
5. Berger, E. A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11:S3-S16.
6. Billich, A., F. Hammerschmid, P. Peichl, R. Wenger, G. Zenke, V. Quesniaux, and B. Rosenwirth. 1995. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol. 69:2451-2461.
7. Bleul, C. C., M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, J. Sodroski, and T. A. Springer. 1996. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382:829-833.
8. 4+ T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J. Virol. 76:1004-1014.
9. Braaten, D., C. Aberham, E. K. Franke, L. Yin, W. Phares, and J. Luban. 1996. Cyclosporin A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J. Virol. 70:5170-5176.
10. Brunn, G. J., C. C. Hudson, A. Sekulic, J. M. Williams, H. Hosoi, P. J. Houghton, J. C. Lawrence, Jr., and R. T. Abraham. 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99-101.
11. Burkly, L., N. Mulrey, R. Blumenthal, and D. S. Dimitrov. 1995. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J. Virol. 69:4267-4273.
12. Buttke, T., J. McCubrey, and T. Owen. 1993. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J. Immunol. Methods 157:233-240.
13. Cantin, R., J.-F. Fortin, G. Lamontagne, and M. Tremblay. 1997. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J. Virol. 71:1922-1930.
14. Chang, L. J., V. Urlacher, T. Iwakuma, Y. Cui, and J. Zucali. 1999. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 6:715-728.
15. Chen, B., K. Saksela, R. Andino, and D. Baltimore. 1994. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J. Virol. 62:654-660.
16. Chiu, M. I., H. Katz, and V. Berlin. 1994. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. USA 91:12574-12578.
17. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. Ponath, L. Wu, C. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
18. Chomczynski, P. 1993. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. BioTechniques 15:532-536.
19. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
20. Clipstone, N. A., and G. R. Crabtree. 1992. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695-697.
21. Cocchi, F., A. L. DeVico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1α, and MIP-1 β as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
22. Coull, J. J., D. Turner, T. Melby, M. R. Betts, R. Lanier, and D. M. Margolis. 2001. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J. Acquired Immune Defic. Syndr. 26:423-434.
23. Daelemans, D., A. M. Vandamme, and E. De Clercq. 1999. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antivir. Chem. Chemother. 10:1-14.
24. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. Sutton, C. Hill, C. David, S. Peiper, T. Schall, D. Littman, and N. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
25. Dumont, F. J., M. J. Staruch, S. L. Koprak, M. R. Melino, and N. H. Sigal. 1990. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144:251-258.
26. Fortin, J.-F., R. Cantin, G. Lamontagne, and M. Tremblay. 1997. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J. Virol. 71:3588-3596.
27. Franke, E. K., and J. Luban. 1996. Inhibition of HIV-1 replication by cyclosporin A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 222:279-282.
28. Frankel, A. D., and J. A. Young. 1998. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67:1-25.
29. Grolleau, A., J. Bowman, B. Pradet-Balade, E. Puravs, S. Hanash, J. A. Garcia-Sanz, and L. Beretta. 2002. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem. 277:22175-22184.
30. Hanke, J. H., L. N. Nichols, and M. E. Coon. 1992. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. Lymphokine Cytokine Res. 11:221-231.
31. Hossain, M. M., J. J. Coull, G. L. Drusano, and D. M. Margolis. 2002. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res. 55:41-52.
32. Jacobson, S. K., R. Y. Calne, and T. G. Wreghitt. 1991. Outcome of HIV infection in transplant patient on cyclosporin. Lancet 337:794.
33. Jacquenet, S., D. Ropers, P. S. Bilodeau, L. Damier, A. Mougin, C. M. Stoltzfus, and C. Branlant. 2001. Conserved stem-loop structures in the HIV-1 RNA region containing the A3 3′ splice site and its cis-regulatory element: possible involvement in RNA splicing. Nucleic Acids Res. 29:464-478.
34. Jefferies, H. B., C. Reinhard, S. C. Kozma, and G. Thomas. 1994. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. USA 91:4441-4445.
35. Kahan, B. D., S. Gibbons, N. Tejpal, S. M. Stepkowski, and T. C. Chou. 1991. Synergistic interactions of cyclosporin and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 51:232-239.
36. Kay, J. E., and C. R. Benzie. 1989. T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506. Immunol. Lett. 23:155-159.
37. Kay, J. E., L. KromweI, S. E. Doe, and M. Denyer. 1991. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72:544-549.
38. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
39. Kimball, P. M., R. H. Kerman, and B. D. Kahan. 1991. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporin. Transplantation 51:486-490.
40. Kitamura, Y., T. Ishikawa, N. Okui, N. Kobayashi, T. Kanda, T. Shimada, K. Miyake, and K. Yoshiike. 1999. Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 20:105-114.
41. Lahm, H., and S. Stein. 1985. Characterization of recombinant human interleukin-2 with micromethods. J. Chromatogr. 326:357-361.
42. Matlin, K. S., H. Reggio, A. Helenius, and K. Simons. 1982. Pathway of vesicular stomatitis virus entry leading to infection. J. Mol. Biol. 156:609-631.
43. Matsushita, S. 2000. Current status and future issues in the treatment of HIV-1 infection. Int. J. Hematol. 72:20-27.
44. Mendez, R., M. G. Myers, Jr., M. F. White, and R. E. Rhoads. 1996. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol. Cell. Biol. 16:2857-2864.
45. Michael, N. L., and J. P. Moore. 1999. HIV-1 entry inhibitors: evading the issue. Nat. Med. 5:740-742.
46. Molnar-Kimber, K. L. 1996. Mechanism of action of rapamycin (Sirolimus, Rapamune). Transplant. Proc. 28:964-969.
47. 1/S-phase growth arrest in T lymphocytes. J. Biol. Chem. 268:3734-3738.
48. Nielsen, F. C., L. Ostergaard, J. Nielsen, and J. Christiansen. 1995. Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway. Nature 377:358-362.
49. O'Keefe, S. J., J. Tamura, R. L. Kincaid, M. J. Tocci, and E. A. O'Neill. 1992. FK-506- and cyclosporin A-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357:692-694.
50. Oberlin, E., A. Amara, F. Bachelerie, C. Bessia, J.-L. Virelizier, F. Arenzana-Seisdedos, O. Schwartz, J.-M. Heard, I. Clark-Lewis, D. F. Legler, M. Loetsher, M. Baggiolini, and B. Moser. 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382:833-835.
51. Okamoto, H., T. P. Cujec, B. M. Peterlin, and T. Okamoto. 2000. HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation. Virology 270:337-344.
52. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
53. Press, N., G. Kimel, M. Harris, B. Yip, K. J. Craib, and J. S. Montaner. 2002. Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens. HIV Clin. Trials 3:17-20.
54. Proudfoot, A. E., T. N. Wells, and P. R. Clapham. 1999. Chemokine receptors-future therapeutic targets for HIV? Biochem. Pharmacol. 57:451-463.
55. Richman, D. D. 2001. HIV chemotherapy. Nature 410:995-1001.
56. Rizzardi, G. P., A. Harari, B. Capiluppi, G. Tambussi, K. Ellefsen, D. Ciuffreda, P. Champagne, P. A. Bart, J. P. Chave, A. Lazzarin, and G. Pantaleo. 2002. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Investig. 109:681-688.
57. Rizzardi, G. P., A. Lazzarin, and G. Pantaleo. 2002. Potential role of immune modulation in the effective long-term control of HIV-1 infection. J. Biol. Regul. Homeost. Agents 16:83-90.
58. Romano, G., M. Kasten, G. De Falco, P. Micheli, K. Khalili, and A. Giordano. 1999. Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression. J. Cell. Biochem. 75:357-368.
59. Rose, N., and A. Lever. 2001. The rapamycin sensitivity of human T-cell leukaemia virus type I-induced T-cell proliferation is mediated independently of the polypyrimidine motifs in the 5′ long terminal repeat. J. Gen. Virol. 82:435-439
60. Saha, K., M. Caruso, and D. J. Volsky. 1997. Human immunodeficiency virus type 1 (HIV-1) infection of herpesvirus saimiri-immortalized human CD4-positive T lymphoblastoid cells: evidence of enhanced HIV-1 replication and cytopathic effects caused by endogenous interferon-γ. Virology 231:1-9.
61. Schwartz, O., J. L. Virelizier, L. Montagnier, and U. Hazan. 1990. A microtransfection method with the luciferase-encoding reporter gene for the assay of human immunodeficiency virus long terminal repeat promoter activity. Gene 88:197-205.
62. Si, Z., B. A. Amendt, and C. M. Stoltzfus. 1997. Splicing efficiency of human immunodeficiency virus type 1 tat RNA is determined by both a suboptimal 3′ splice site and a 10 nucleotide exon splicing silencer element located within tat exon 2. Nucleic Acids Res. 25:861-867.
63. Staffa, A., and A. Cochrane. 1995. Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1. Mol. Cell. Biol. 15:4597-4605.
64. Staffa, A., and A. Cochrane. 1994. The tat/rev intron of human immunodeficiency virus type 1 is inefficiently spliced because of suboptimal signals in the 3′ splice site. J. Virol. 68:3071-3079.
65. Gag: mechanism for antiviral effects of cyclosporin A. Virology 245:197-202.
66. Suzuki, Y. J., B. B. Aggarwal, and L. Packer. 1992. α-Lipoic acid is a potent inhibitor of NF-κB activation in human T cells. Biochem. Biophys. Res. Commun. 189:1709-1715.
67. Tailor, C. S., and D. Kabat. 1997. Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains. J. Virol. 71:9383-9391.
68. Tange, T. O., and J. Kjems. 2001. Sf2/asf binds to a splicing enhancer in the third hiv-1 tat exon and stimulates u2af binding independently of the rs domain. J. Mol. Biol. 312:649-662.
69. Taube, R., K. Fujinaga, J. Wimmer, M. Barboric, and B. M. Peterlin. 1999. Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. Virology 264:245-253.
70. Terada, N., H. R. Patel, K. Takase, K. Kohno, A. C. Nairn, and E. W. Gelfand. 1994. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc. Natl. Acad. Sci. USA 91:11477-11481.
71. Thali, M., A. Bukovsky, E. Kondo, B. Rosenwirth, C. T. Walsh, J. Sodroski, and H. G. Gottlinger. 1994. Functional association of cyclophilin A with HIV-1 virions. Nature 372:363-365.
72. Thomas, G., and M. N. Hall. 1997. TOR signalling and control of cell growth. Curr. Opin. Cell Biol. 9:782-787.
73. Vandamme, A. M., K. Van Vaerenbergh, and E. De Clercq. 1998. Antihuman immunodeficiency virus drug combination strategies. Antivir. Chem. Chemother. 9:187-203.
74. Weller, I. V., and I. G. Williams. 2001. ABC of AIDS Antiretroviral drugs. Br. Med. J. 322:1410-1412.
75. + T-cell line. Proc. Natl. Acad. Sci. USA 87:6713-6717.
76. Yee, J. K., A. Miyanohara, P. Laporte, K. Bouic, B. J. C., and T. Friedmann. 1994. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91:9564-9568.
77. Yin, L., D. Braaten, and J. Luban. 1998. Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J. Virol. 72:6430-6436.
78. Zheng, X. X., T. B. Strom, and A. W. Steele. 1994. Quantitative comparison of rapamycin and cyclosporin effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction. Transplantation 58:87-92.